Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
University of Manchester
Mánchester, Reino UnidoPublicacions en col·laboració amb investigadors/es de University of Manchester (83)
2024
-
Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy
Radiotherapy and Oncology, Vol. 198
-
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study
Cancer, Vol. 130, Núm. 19, pp. 3278-3288
-
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Nature Communications , Vol. 15, Núm. 1
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes
The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106
-
Obstetric complications and clinical presentation in first episode of psychosis
Acta Neuropsychiatrica, Vol. 35, Núm. 3, pp. 156-164
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Mortality risk prediction of high-sensitivity C-reactive protein in suspected acute coronary syndrome: A cohort study
PLoS Medicine, Vol. 19, Núm. 2
-
Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis
Movement Disorders, Vol. 37, Núm. 5, pp. 1028-1039
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
ESMO Open, Vol. 6, Núm. 2
-
Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis
Nephrology Dialysis Transplantation, Vol. 36, Núm. 12, pp. 2308-2320
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2020
-
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909